ALLOGENE THERAPEUTICS INC (ALLO)
US0197701065 - Common Stock
| TTM (2024-9-30) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
| Net Income | -286.91M | -327.26M | -332.63M | -257.01M | -250.22M | |||
| Depreciation Amortization | 13.88M | 14.20M | 14.30M | 10.45M | 7.59M | |||
| Change In Working Capital | -33.47M | -15.30M | 3.71M | -32.09M | 53.92M | |||
| Other non cash items | 89.19M | 90.64M | 94.11M | 93.83M | 73.62M | |||
| OPERATING CASH FLOW | -217.31M | -237.73M | -220.52M | -184.81M | -115.09M | |||
| CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
| Capital Expenditure | -613.00K | -1.52M | -5.19M | -21.45M | -65.96M | |||
| Other Investing Activity | 88.84M | 164.81M | 111.35M | 185.10M | -439.17M | |||
| INVESTING CASH FLOW | 88.21M | 163.29M | 106.16M | 163.66M | -505.12M | |||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
| Debt Issued/Reduced | N/A | N/A | N/A | N/A | 0.00 | |||
| Stock Issued/Repurchased | 108.81M | 95.69M | 2.95M | 11.96M | 633.59M | |||
| FINANCING CASH FLOW | 111.09M | 95.69M | 2.95M | 11.96M | 633.59M | |||
| CHANGE IN CASH | -18.01M | 21.25M | -111.41M | -9.19M | 13.38M | |||
| FREE CASH FLOW | ||||||||
| Operating Cash Flow | -217.31M | -237.73M | -220.52M | -184.81M | -115.09M | |||
| Capital Expenditure | -613.00K | -1.52M | -5.19M | -21.45M | -65.96M | |||
| FREE CASH FLOW | -217.92M | -239.25M | -225.71M | -206.26M | -181.05M | |||
All data in USD